Market Research Logo

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) - Pipeline Review, H2 2016

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) - Pipeline Review, H2 2016’, provides an overview of the Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis)
    • The report reviews pipeline therapeutics for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) therapeutics and enlists all their major and minor projects
    • The report assesses Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis)
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis)
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Overview
    Therapeutics Development
    Pipeline Products for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) - Overview
    Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) - Therapeutics under Development by Companies
    Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) - Pipeline Products Glance
    Late Stage Products
    Clinical Stage Products
    Early Stage Products
    Unknown Stage Products
    Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) - Products under Development by Companies
    Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) - Companies Involved in Therapeutics Development
    Bionovis SA
    Bristol-Myers Squibb Company
    ChemoCentryx, Inc.
    Coherus BioSciences, Inc.
    Genor BioPharma Co., Ltd.
    GlaxoSmithKline Plc
    KPI Therapeutics, Inc.
    Panacea Biotec Limited
    Sandoz International GmbH
    The International Biotechnology Center (IBC) Generium
    Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    abatacept - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    belimumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CCX-168 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    dalazatide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    mepolizumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    rituximab biosimilar - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    rituximab biosimilar - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    rituximab biosimilar - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    rituximab biosimilar - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    rituximab biosimilar - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    rituximab biosimilar - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    rituximab biosimilar - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) - Dormant Projects
    Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) - Discontinued Products
    Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) - Product Development Milestones
    Featured News & Press Releases
    Jun 16, 2016: ChemoCentryx Announces Positive Top-Line Results for CCX168 from the Phase II ANCA-Associated Vasculitis CLASSIC Study and Advances Plans to Initiate Phase III Development
    Jun 01, 2016: ChemoCentryx Receives European Medicines Agency PRIority MEdicines (PRIME) Designation for Accelerated Assessment of Complement 5a Receptor Inhibitor CCX168 for Treatment of Patients with ANCA-Associated Vasculitis
    May 23, 2016: ChemoCentryx Announces Presentation of Positive Results from Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168 at the 53rd ERA-EDTA Congress
    Apr 28, 2016: ChemoCentryx Receives FDA Orphan Products Development Grant for Orally Administered Complement 5a Receptor Inhibitor CCX168 for Treatment of ANCA-Associated Vasculitis
    Jan 06, 2016: ChemoCentryx Announces Positive Results in Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168
    Nov 09, 2015: Kineta Presents New Data Demonstrating Positive, Predictive Responses to Dalazatide in Psoriasis Patients and in Lupus, ANCA Vasculitis Studies at American College of Rheumatology Annual Meeting
    Apr 21, 2015: Kineta, University of Groningen Present New, Positive Data for Dalazatide in ANCA Vasculitis, an Orphan Disease
    Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis
    Nov 17, 2014: ChemoCentryx's Orally Administered C5aR Inhibitor CCX168 Shows Benefit In Non-Renal ANCA Vasculitis Disease Activity, In Addition To Previously Shown Kidney Disease Improvements
    Jun 02, 2014: ChemoCentryx's Orally-Administered Complement 5a Receptor Inhibitor, CCX168, Shows Benefit in ANCA-Associated Vasculitis Based on Birmingham Vasculitis Activity Score and Renal Disease Measurements
    Feb 14, 2014: GSK announces start of Phase lll study for mepolizumab in patients with Eosinophilic Granulomatosis with Polyangiitis
    Dec 03, 2013: ChemoCentryx Announces Positive Top-Line CCX168 Phase II Data in ANCA-Associated Renal Vasculitis
    Nov 10, 2010: ChemoCentryx Presents Positive Phase I Results For CCX168 At Annual American College Of Rheumatology Meeting
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), H2 2016
    Number of Products under Development by Companies, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Comparative Analysis by Unknown Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) - Pipeline by Bionovis SA, H2 2016
    Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) - Pipeline by Bristol-Myers Squibb Company, H2 2016
    Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) - Pipeline by ChemoCentryx, Inc., H2 2016
    Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) - Pipeline by Coherus BioSciences, Inc., H2 2016
    Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) - Pipeline by Genor BioPharma Co., Ltd., H2 2016
    Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) - Pipeline by GlaxoSmithKline Plc, H2 2016
    Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) - Pipeline by KPI Therapeutics, Inc., H2 2016
    Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) - Pipeline by Panacea Biotec Limited, H2 2016
    Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) - Pipeline by Sandoz International GmbH, H2 2016
    Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) - Dormant Projects, H2 2016
    Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) - Discontinued Products, H2 2016
    List of Figures
    Number of Products under Development for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), H2 2016
    Number of Products under Development by Companies, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Targets, H2 2016
    Number of Products by Stage and Targets, H2 2016
    Number of Products by Mechanism of Actions, H2 2016
    Number of Products by Stage and Mechanism of Actions, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Molecule Types, H2 2016
    Number of Products by Stage and Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report